Back
EAPC Premium Access

Real world prospective one year monocentric follow up study investigating novel lipid lowering agents class proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab

Session: Poster Session 2 - Risk Factors and Prevention - Lipids
Topic: Lipids
Speaker: Mr M. Poudel (Bielefeld, DE)
Event: EuroPrevent 2019

Congress Presentation

About the speaker

Mr Madan Raj Poudel

University Clinic OWL, Bielefeld (Germany)
0 follower

15 more presentations in this session

Verification of the dutch criteria for familial hypercholesterolemia among a contingent of patients in southern Bulgaria

Speaker: Doctor L. Kitova (Plovdiv, BG)

Access
Slides
Thumbnail

Lipid control in very high cardiovascular risk patients: what is the trend?

Speaker: Doctor S. Cardoso Torres (Porto, PT)

Access
Abstract
Thumbnail

Physician-related factors associated with adherence to national guidelines for dyslipidemia management in primary care

Speaker: Professor N. Pogosova (Moscow, RU)

Access
Abstract
Thumbnail

Cardiovascular risk according to SCORE and lipoprotein (a) - Does the association exist in Saint Petersburg population?

Speaker: Doctor E. Kolesova (Saint-Petersburg, RU)

Access
Abstract
Thumbnail

The role of lipoprotein a as a cardiovascular risk factor in primary prevention screening

Speaker: Doctor J. Gilis-Januszewski (Bad Oeynhausen, DE)

Access
Abstract
Thumbnail

Access the full session

Poster Session 2 - Risk Factors and Prevention - Lipids

Speakers: Mr M. Poudel, Doctor L. Kitova, Doctor S. Cardoso Torres, Professor N. Pogosova, Doctor E. Kolesova...
Access
Thumbnail

About the event

Image

EuroPrevent 2019

11 April - 13 April 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb